HC restrains Patanjali’s ad hitting Dabur chyawanprash

Mumbai: Patanjali Ayurved’s product advertisements appear to be hitting a legal hurdle from several quarters. After the Bombay high court restrained Baba Ramdev’s company from advertising its bath soap brand, which allegedly disparaged rival Hindustan Unilever’s soap brands, the Delhi high court on Thursday passed an ad-interim injunction against Patanjali’s chyawanprash commercial.

The chyawanprash advertisement was allegedly disparaging Dabur India’s chyawanprash brand. The division bench of Delhi HC headed by the chief justice, while hearing an appeal, granted the injunction restraining the telecast and circulation of Patanjali’s said chyawanprash advertisement.

Dabur Chyawanprash, with annual sales of Rs 280 crore, is a market leader in the category. In its order, the Delhi HC bench noted, “We are satisfied that the appellant has made out a prima facie case for grant of ad-interim protection. Undoubtedly, grave and irreparable loss and damage would ensure to the appellant if interim protection is not granted.”

When contacted, a Dabur India spokesperson confirmed that the Delhi HC has granted ad-interim injunction to the advertisement. “However, we would not be able to comment further as the matter is sub judice,” the spokesperson said. When contacted, a Patanjali Ayurved spokesperson said, “We will file our reply to the honourable court after seeking the details of the order. Our communication strategy is simple. We want to convey to the consumers the benefits of using our healthy and natural products as against other products which may be harmful.”

Subscribe ETHealthworld Newsletter

Lyrica, known generically as pregabalin, was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain, which soon became its main market.

With this acquisition, Nephroplus will further strengthen its servicing capacity as the dominant dialysis centre network and will have a presence in 18 states of India with 176 centers across 97 cities.